Sangamo Therapeutics, Inc. Aktie News

Auktionsverfahren für das ST-503-Programm gegen chronische neuropathische Schmerzen eingeleitet, Abschluss erwartet im vierten Quartal 2026 Zuvor angekündigte Asset-Verkaufsabschlüsse mit PTC und Lilly wurden abgeschlossen und generierten 163,55 Mio. USD Bruttozahlungseinnahmen RICHMOND, Calif., 13. Okt. 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCID Basic Market: SGMOQ) gab heute d...

Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as “stalking horse” bidders in a court-supervised auction process Sangamo has secured commitment for debtor-in-possession (DIP) financing to support ongoing operations RICHMOND, Calif., June 23, 2026 (GLOBE NE...

RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the company's pipeline and financial resources, it has retained Raymond James as its financial advisor to assist in evaluating a full range of strategic alternatives to advance its promising pipeline and t...

Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503 in chronic neuropathic pain.

RICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three Sangamo abstracts for presentation at the 29th ASGCT Annual Meeting being held May 11-15, 2026, in-person in Boston, MA and in a virtual format.

RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that its common stock will transition from trading on The Nasdaq Capital Market to the OTCQB Venture Market on Tuesday, May 5, 2026.